Novavax Wins FDA Emergency Approval for 2024-2025 COVID-19 Vaccine Formula
Novavax, a global leader in protein-based vaccines, has announced that its updated COVID-19 vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705), has received
Read moreNovavax, a global leader in protein-based vaccines, has announced that its updated COVID-19 vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705), has received
Read morePfizer and BioNTech have announced that the U.S. Food and Drug Administration (FDA) has approved their supplemental Biologics License Application
Read moreNovel T Cell Staining Reagents Now Available at imusyn’s Web Shop imusyn is excited to announce the release of Dyemer
Read morePfizer and BioNTech have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the
Read moreimusyn’s Dyemer & myDyemer are a pioneering class of ready-to-use and loadable T Cell staining reagents, developed for precise quantification
Read moreimusyn offers an unmatched portfolio of top-tier recombinant HLA class I and class II proteins, produced as truncated, soluble antigens
Read moreimusyn’s imuPep Class I Peptide Binding Analysis is designed to determine the stability of peptide/HLA class I complexes, allowing researchers
Read moreResearchers have made a significant leap forward in the fight against drug-resistant tuberculosis (TB), according to a recent study published in
Read moreAmerican clinical-stage biotechnology company Vaxart, Inc. has announced that the United States Biomedical Advanced Research and Development Authority (BARDA) granted
Read moreIn a groundbreaking development for the vaccine development sector, biotech company Valneva SE announced, that the U.S. Food and Drug
Read more